gucancerssympalt Genitourinary Cancers Symposium 2015

February 26 - 28, 2015

Rosen Shingle Creek
Orlando, FL USA

 

 

 #GU15 - Androgen deprivation therapy, cardiovascular risk, and multidisciplinary management of the prostate cancer patient: A German perspective - Session Highlights

read more

 

#GU15 - AR splice variant 7 (AR-V7) could be a marker for treatment selection in metastatic castrate-resistant prostate cancer

read more

 

#GU15 - Novel imaging modalities boost detection of early metastatic disease in prostate cancer - Session Highlights

read more

 

#GU15 - Progress and challenges in penile, urethral, and testicular cancer - Session Highlights

read more

 

#GU15 - Prostate cancer in 2014- 2015: Advances and ongoing challenges in therapeutics, biomarkers, and precision medicine

read more

 

#GU15 - Renal cell cancer keynote: Management of RCC: Future needs and opportunities - Session Highlights

read more

 

#GU15 - Year in review: Renal cell cancer - Session Highlights

read more

 

#GU15 - Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial - Session Highlights

read more

 

#GU15 - Metabolic pathways - Session Highlights

read more

 

#GU15 - Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma - Session Highlights

read more

 

#GU15 - Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience - Session Highlights

read more

 

#GU15 - Correlation of baseline serum testosterone and PSA at 7 months in patients with new metastatic prostate cancer treated with continuous ADT - Session Highlights

read more

 

#GU15 - Treatment patterns of new metastatic castration-resistant prostate cancer (mCRPC) therapies: Real-world evidence from three datasets - Session Highlights

read more

 

#GU15 - AR modulation optimized for response in splice variant (ARMPR3-SV): A RCT of galeterone vs enzalutamide in men expressing ARv7 in mCRPC - Session Highlights

read more

 

#GU15 - Poster: Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup

read more

 

#GU15 - Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel subgroup - Session Highlights

read more

 

#GU15 - Prior and concurrent use of abiraterone and enzalutamide with Ra-223 in an expanded access setting - Session Highlights

read more

 

#GU15 - Radium-223 dichloride (Ra-223) in U.S. Expanded Access Program (EAP) - Session Highlights

read more

 

#GU15 - Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel - Session Highlights

read more

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

read more

 

#GU15 - Effect of early detection of asymptomatic visceral recurrence after radical cystectomy on prognosis in patients with muscle invasive bladder cancer - Session Highlights

read more

 

#GU15 - Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone - Session Highlights

read more

 

#GU15 - Urothelial carcinoma keynote - Session Highlights

read more

 

#GU15 - Exploring the effects of abiraterone/enzalutamide failure prior to the initiation of radium-223 dichloride in men with metastatic castrate-resistant prostate cancer - Session Highlights

read more

 

#GU15 - The impact of time to metastasis on survival in treatment-naïve prostate cancer patients - Session Highlights

read more

 

#GU15 - A multidisciplinary clinic to mitigate the impact of androgen deprivation therapy in prostate cancer: A pilot study - Session Highlights

read more

 

#GU15 - Contemporary use of radium-223 (Ra-223) in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Feasibility and safety - Session Highlights

read more

 

#GU15 - Best of journals: mCRPC treatment - Session Highlights

read more

 

#GU15 - Urothelial carcinoma: Year in review - Session Highlights

read more

 

#GU15 - The biology of bladder cancer metastasis - Session Highlights

read more

 

#GU15 - What is new in systemic therapy for urothelial tumors? - Session Highlights

read more

 

#GU15 - Best of journals: Prostate cancer - Session Highlights

read more

 

#GU15 - Best of journals - Session Highlights

read more

 

#GU15 - Dynamic changes in biomarkers for immune response to sipuleucel-T for mCRPC - Session Highlights

read more

 

#GU15 - FANCA loss as a biomarker of platinum sensitivity in prostate cancer - Session Highlights/span>

read more

 

#GU15 - Phase II trial of abiraterone acetate (AA) treatment for metastatic prostate cancer (PC) patients with a PSA of more than four following initial androgen deprivation therapy: SWOG S1014 - Session Highlights

read more

 

#GU15 - Are patients with Gleason 6 pathology safe from developing metastatic castration-resistant prostate cancer (mCRPC)? - Session Highlights

read more

 

#GU15 - Testosterone levels in metastatic castration resistant prostate cancer (mCRPC) - Session Highlights

read more

 

#GU15 - Poster: 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA

read more

  

#GU15 - 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from ALSYMPCA - Session Highlights

read more

 

#GU15 - Place of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy: A phase III trial - Session Highlights

read more

 

#GU15 - Prostate Cancer Keynote: Can epigenetic alterations in human cancers be exploited for cancer screening, detection, diagnosis and treatment? - Session Highlights

read more

 

#GU15 - Prostate cancer: Year in review - Session Highlights

read more

 

#GU15 - ASCENDE-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer - Session Highlights

read more

 

#GU15 - ADT plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial - Session Highlights

read more

 

#GU15 - Characterization of abiraterone responses in African American men with castrate resistant prostate cancer - Session Highlights

read more

 

#GU15 - Effects of radium-223 dichloride with docetaxel (D) versus D on PSA and bone alkaline phosphatase in patients with castration-resistant prostate cancer and bone metastases: A phase 1/2a clinical trial - Session Highlights

read more

 

#GU15 - Poster: Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302

read more

 

#GU15 - Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients with metastatic castration-resistant prostate cancer (mCRPC): Post-hoc analysis of COU-AA-302 - Session Highlights

read more

 

#GU15 - Poster: External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial

read more

 

#GU15 - External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial - Session Highlights

read more

 

#GU15 - Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT - Session Highlights

read more

 

#GU15 - AR-based biomarker association with response to abiraterone in mCRPC - Session Highlights

read more

 

#GU15 - Antigen-specific immune responses through 24 months in the STAND trial: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T and androgen deprivation therapy in biochemically-recurrent prostate cancer - Session Highlights

read more

 

#GU15 - Assessment of corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate in mCRPC - Session Highlights

read more

 

#GU15 - Risk of cardiovascular events with degarelix versus leuprolide after biochemical relapse of prostate cancer: Exploratory analysis of a randomized controlled trial - Session Highlights

read more

 

#GU15 - Increase in higher risk prostate cancer cases following new screening recommendation by the US Preventive Services Task Force (USPSTF) - Session Highlights

read more

 

#GU15 - Early radiation response between GnRH agonist versus antagonist combined with radiotherapy in high-risk prostate cancer - Session Highlights

read more

 

#GU15 - Impact of CCP test on personalizing treatment decisions: Results from a prospective registry of newly diagnosed prostate cancer patients - Session Highlights

read more

 

#GU15 - Abstract highlights: AR splice variant 7 (AR-V7) and response to taxanes in men with mCRPC - Session Highlights

read more

 

#GU15 - Bench to bedside: Androgen resistance - Session Highlights

read more

 

#GU15 - Clinical context: Using new imaging modalities to identify early metastatic disease - Session Highlights

read more

 

#GU15 - Role of local therapy - Session Highlights

read more

 

#GU15 - A multi-institutional prospective trial in the United States confirms the 4K Score accurately identifies men with high-grade prostate cancer - Session Highlights

read more

 

#GU15 - Biomarkers for prostate cancer: Why aren’t we using them and where do we go from here? - Session Highlights

read more

 

#GU15 - Hormonal therapy: How long is enough? - Session Highlights

read more

 

#GU15 - Who can receive shorter-course radiotherapy? Hypofractionation and stereotactic body radiation therapy - Session Highlights

read more

 

#GU15 - Individualized treatment decisions for localized prostate cancer: Decision aids and quality of life outcomes - Session Highlights

read more

 

Bayer presents latest oncology research at ASCO GU 2015

read more

 

Early evidence of increase in higher-risk prostate cancers from 2011-2013

read more

 

Active surveillance of intermediate-risk prostate cancer associated with decreased survival

read more

 

Men who have had testicular cancer are more likely to develop prostate cancer, although overall risk of developing aggressive disease is low

read more

 

 

Adjuvant sorafenib and sunitinib do not improve outcomes in locally advanced kidney cancer

read more

 

 

Androgen receptor abnormality may not be associated with primary resistance to taxane chemotherapy

read more